May 1968 Vol. LXXXII No. 5

The Journal of Laryngology and Otology

EDITED BY
G. H. BATEMAN

ASSISTANT EDITOR
LIONEL TAYLOR

Contents

Headley Brothers Ltd

Ashford, Kent

Annual Subscription £5/5/0 net, U.S.A. $15 *Monthly, 12/6 net post free*

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

The Journal of Laryngology and Otology

(FOUNDED in 1887 by MORELL MACKENZIE and NORRIS WOLFENDEN)

EDITED BY

G. H. BATEMAN

ASSISTANT EDITOR

LIONEL TAYLOR

---

1. Original articles which have not been published elsewhere are invited and should be sent to the Editor. They are considered for publication on the understanding that they are contributed to this *Journal* solely. Reproduction elsewhere, in whole or in part, is not permitted without the previous written consent of the Author and Editor and the customary acknowledgment must be made.

2. Manuscripts should be typewritten, on one side only of the paper, and well spaced. Captions to illustrations should be typed on a separate sheet and sent at the same time as original photographs, etc.

The Harvard system of recording references should be used, e.g. GREEN, C., and BROWN, D. (1951) *J. Laryng.*, 65, 33. Abbreviations of Journals should follow the style recommended in *World Medical Periodicals*, published by World Health Organization, 1952.

It is most important that authors should verify *personally* the accuracy of every reference before submitting a paper for publication.

3. Galley proofs and engraver's proofs of illustrations are sent to the author. Corrections, which should be kept to a minimum, must be clearly marked, and no extra matter added. Proofs should be returned within 5 days.

4. Illustration blocks will normally be held by the Printers for three years, after which they will be destroyed. Any author is entitled to have these returned to him, but a request for this must be sent within three years of the appearance of the article, to HEADLEY BROTHERS LTD., The Invicta Press, Ashford, Kent. Coloured illustrations will be charged to authors, unless a special grant is authorized by the Editor.

5. Orders for reprints must be sent when returning galley proofs, and for this purpose special forms are supplied.

6. Editorial communications may be addressed to THE EDITOR, *Journal of Laryngology*, c/o HEADLEY BROTHERS LTD., The Invicta Press, Ashford, Kent.

7. The annual subscription is five guineas sterling (U.S.A. $15) post free, and payable in advance.

8. Single copies will be on sale at 12s. 6d. each; copies of parts up to Vol. LXIII which are available may be purchased at 7s. 6d. each.

9. All subscriptions, advertising and business communications should be sent to the publishers, HEADLEY BROTHERS LTD., The Invicta Press, Ashford, Kent.

United States of America

Orders for this *Journal* may be sent through local booksellers, or to STECHERT-HAFNER, INC., 31-33 East 10th Street, New York, or direct to the publishers, HEADLEY BROTHERS LTD., The Invicta Press, Ashford, Kent, England.

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

Table 2

Blood urea mg/100 ml	Serum creatinine mg/100 ml	Creatinine clearance mg/min	Recommended maximum dosage of Ceporin grams daily
60 to 100	1·2 to 4	>10	2·0
100 to 200	4 to 6	5 to 10	1·0
>200	>6	<5	0·5

Side effects and toxicity
With a dosage of 6 grams or more daily, hyaline casts have appeared temporarily in the urine of some patients, occasionally accompanied by scanty other cellular elements. There have also been rare reports of disturbance of renal function associated with high blood levels of Ceporin. It is important, therefore, when using high doses of the drug (6 grams or more daily) or when renal function is impaired, to avoid abnormally high blood levels of Ceporin. Dosage should be adjusted carefully in patients with severe renal impairment in accordance with blood levels of the drug (see section on dosage recommendations for patients with impaired renal function). As with other antibiotics, Ceporin should be administered with caution to patients with a history of allergy, especially to drugs (including penicillin). Ceporin is usually tolerated well by patients allergic to penicillin, but cross-reaction with penicillin has been encountered rarely. Ceporin occasionally causes hypersensitivity reactions, mostly skin rashes. If this happens the drug should be stopped and not used again in that patient. Very rarely an anaphylactic reaction has developed. In this event the drug should be discontinued immediately and the patient treated at once with the usual agents (adrenaline, antihistamines and an intravenous corticosteroid). A few cases of reversible neutropenia have been reported and a temporary slight rise in serum glutamic-oxaloacetic transaminase has been noted. Reversible nystagmus and signs of cerebral irritation have occurred following intrathecal administration of 100 mg or more, but not when the maximum adult intrathecal dose does not exceed 50 mg. There has been no laboratory or clinical evidence of teratogenicity or embryopathic effects but, as with all drugs, Ceporin should be used with caution in the early months of pregnancy.

Legal restriction
To be supplied on prescription only
(Therapeutic Substances Act: Part II)

Presentation
Ceporin is issued in vials containing 250 mg, 500 mg and 1 gram of cephaloridine, packed singly and in boxes of five. Vials containing 100 mg of cephaloridine are packed in boxes of five only.



Ceporin is a Glaxo trade mark

Detailed literature available on request

Glaxo Laboratories Ltd
Greenford, Middlesex

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press

https://doi.org/10.1017/S0022215100068900 Published online by Cambridge University Press